Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Financial Info
: Financials

Financials

v3.7.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 18,941 $ 19,175
Marketable securities-available for sale, at fair value 7,180 23,841
Prepaid expenses and other 1,019 3,343
Total current assets 27,140 46,359
Property and equipment, net 150 350
Restricted cash 89 132
Intangible asset 120 120
Security deposits 11 57
Total assets 27,510 47,018
Current liabilities:    
Accounts payable 872 3,049
Accrued expenses 1,244 3,601
Total current liabilities 2,116 6,650
Deferred rent payable 33 106
Total liabilities 2,149 6,756
Commitments (See Note 10)  
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.001 par value; 15,000,000 shares authorized; 3,918,111 and 1,883,167 shares issued and outstanding as of December 31, 2016 and 2015, respectively, 2,496 and 1,760 shares to be issued as of December 31, 2016 and 2015, respectively 4 2
Additional paid in capital 166,604 142,675
Accumulated deficit (141,240) (102,398)
Accumulated other comprehensive income loss (7) (17)
Total stockholders' equity 25,361 40,262
Total liabilities and stockholders' equity $ 27,510 $ 47,018
v3.7.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
COSTS AND EXPENSES:    
Research and development $ 28,533 $ 35,504
General and administrative 10,436 12,658
Total costs and expenses 38,969 48,162
Operating loss (38,969) (48,162)
Interest income, net 127 108
NET LOSS $ (38,842) $ (48,054)
Net loss per common share, basic and diluted (in dollars per share) $ (15.41) $ (28.62)
Weighted average common shares outstanding, basic and diluted (in shares) 2,521,016 1,679,106
v3.7.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (38,842) $ (48,054)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 206 161
Stock-based compensation 3,266 4,389
Loss on disposal of property and equipment 133
Changes in operating assets and liabilities:    
Prepaid expenses 2,370 (2,524)
Accounts payable (2,185) 1,583
Accrued expenses (2,190) 1,874
Security deposit (11)
Other long term liabilities (73) 54
Net cash used in operating activities (37,315) (42,528)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and fixtures (66) (118)
Purchase of intangible asset (120)
Purchase of marketable securities (28,643)
Proceeds from restricted cash 45
Maturities of marketable securities 16,615 4,710
Net cash provided by (used in) investing activities 16,594 (24,171)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants 9
Proceeds, net of expenses of $1,866 and $3,484, from sale of common stock 20,498 47,685
Net cash provided by financing activities 20,498 47,694
Effect of currency rate change on cash (11) (4)
Net decrease in cash and cash equivalents (234) (19,009)
Cash and cash equivalents, beginning of the year 19,175 38,184
Cash and cash equivalents, end of year 18,941 19,175
Non-cash financing activities:    
Issuance of common stock under employee stock purchase plan $ 167 $ 160